Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET.

Normandin MD, Petersen KF, Ding YS, Lin SF, Naik S, Fowles K, Skovronsky DM, Herold KC, McCarthy TJ, Calle RA, Carson RE, Treadway JL, Cline GW.

J Nucl Med. 2012 Jun;53(6):908-16. doi: 10.2967/jnumed.111.100545. Epub 2012 May 9.

2.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, Pettersen J, Minich ML, Filipski KJ, Jones CS, Tu M, Aspnes G, Risley H, Bian J, Stevens BD, Bourassa P, D'Aquila T, Baker L, Barucci N, Robertson AS, Bourbonais F, Derksen DR, Macdougall M, Cabrera O, Chen J, Lapworth AL, Landro JA, Zavadoski WJ, Atkinson K, Haddish-Berhane N, Tan B, Yao L, Kosa RE, Varma MV, Feng B, Duignan DB, El-Kattan A, Murdande S, Liu S, Ammirati M, Knafels J, Dasilva-Jardine P, Sweet L, Liras S, Rolph TP.

J Med Chem. 2012 Feb 9;55(3):1318-33. doi: 10.1021/jm2014887. Epub 2012 Jan 24.

PMID:
22196621
3.

Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform.

Enayetallah AE, Ziemek D, Leininger MT, Randhawa R, Yang J, Manion TB, Mather DE, Zavadoski WJ, Kuhn M, Treadway JL, des Etages SA, Gibbs EM, Greene N, Steppan CM.

PLoS One. 2011;6(11):e27009. doi: 10.1371/journal.pone.0027009. Epub 2011 Nov 4.

4.

Islet-selectivity of G-protein coupled receptor ligands evaluated for PET imaging of pancreatic β-cell mass.

Cline GW, Zhao X, Jakowski AB, Soeller WC, Treadway JL.

Biochem Biophys Res Commun. 2011 Sep 2;412(3):413-8. doi: 10.1016/j.bbrc.2011.07.077. Epub 2011 Jul 28.

PMID:
21820405
5.

Defective glycogenesis contributes toward the inability to suppress hepatic glucose production in response to hyperglycemia and hyperinsulinemia in zucker diabetic fatty rats.

Torres TP, Fujimoto Y, Donahue EP, Printz RL, Houseknecht KL, Treadway JL, Shiota M.

Diabetes. 2011 Sep;60(9):2225-33. doi: 10.2337/db09-1156. Epub 2011 Jul 19.

6.

Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes.

Yang J, MacDougall ML, McDowell MT, Xi L, Wei R, Zavadoski WJ, Molloy MP, Baker JD, Kuhn M, Cabrera O, Treadway JL.

BMC Genomics. 2011 Jun 1;12:281. doi: 10.1186/1471-2164-12-281.

7.

Impact of a glycogen phosphorylase inhibitor and metformin on basal and glucagon-stimulated hepatic glucose flux in conscious dogs.

Torres TP, Sasaki N, Donahue EP, Lacy B, Printz RL, Cherrington AD, Treadway JL, Shiota M.

J Pharmacol Exp Ther. 2011 Jun;337(3):610-20. doi: 10.1124/jpet.110.177899. Epub 2011 Mar 1.

8.

1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.

Andrews KM, Beebe DA, Benbow JW, Boyer DA, Doran SD, Hui Y, Liu S, McPherson RK, Neagu C, Parker JC, Piotrowski DW, Schneider SR, Treadway JL, VanVolkenberg MA, Zembrowski WJ.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1810-4. doi: 10.1016/j.bmcl.2011.01.055. Epub 2011 Jan 31.

PMID:
21324688
9.

Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes.

Singhal T, Ding YS, Weinzimmer D, Normandin MD, Labaree D, Ropchan J, Nabulsi N, Lin SF, Skaddan MB, Soeller WC, Huang Y, Carson RE, Treadway JL, Cline GW.

Mol Imaging Biol. 2011 Oct;13(5):973-84. doi: 10.1007/s11307-010-0406-x. Epub 2010 Sep 8.

10.

The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.

Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, Abdiche Y, Stone DM, Paralkar VM.

J Pharmacol Exp Ther. 2010 Apr;333(1):2-13. doi: 10.1124/jpet.109.164129. Epub 2010 Jan 20.

11.

(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.

Ammirati MJ, Andrews KM, Boyer DD, Brodeur AM, Danley DE, Doran SD, Hulin B, Liu S, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soglia CB, Treadway JL, VanVolkenburg MA, Wilder DC, Piotrowski DW.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):1991-5. doi: 10.1016/j.bmcl.2009.02.041. Epub 2009 Feb 13.

PMID:
19275964
12.

The hepatic PP1 glycogen-targeting subunit interaction with phosphorylase a can be blocked by C-terminal tyrosine deletion or an indole drug.

Kelsall IR, Munro S, Hallyburton I, Treadway JL, Cohen PT.

FEBS Lett. 2007 Oct 2;581(24):4749-53. Epub 2007 Sep 6.

13.

(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.

Wright SW, Ammirati MJ, Andrews KM, Brodeur AM, Danley DE, Doran SD, Lillquist JS, Liu S, McClure LD, McPherson RK, Olson TV, Orena SJ, Parker JC, Rocke BN, Soeller WC, Soglia CB, Treadway JL, Vanvolkenburg MA, Zhao Z, Cox ED.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5638-42. Epub 2007 Aug 22.

PMID:
17822893
15.

Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.

Ekins S, Mankowski DC, Hoover DJ, Lawton MP, Treadway JL, Harwood HJ Jr.

Drug Metab Dispos. 2007 Mar;35(3):493-500. Epub 2006 Dec 28. Erratum in: Drug Metab Dispos. 2007 Jul;35(7):1246.

16.

cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.

Wright SW, Ammirati MJ, Andrews KM, Brodeur AM, Danley DE, Doran SD, Lillquist JS, McClure LD, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soeller WC, Soglia CB, Treadway JL, VanVolkenburg MA, Wang H, Wilder DC, Olson TV.

J Med Chem. 2006 Jun 1;49(11):3068-76.

PMID:
16722626
17.

Establishment of correlation between in vitro enzyme binding potency and in vivo pharmacological activity: application to liver glycogen phosphorylase a inhibitors.

Yu LJ, Chen Y, Treadway JL, McPherson RK, McCoid SC, Gibbs EM, Hoover DJ.

J Pharmacol Exp Ther. 2006 Jun;317(3):1230-7. Epub 2006 Mar 14.

18.

The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits.

Flynn DM, Smith AH, Treadway JL, Levy CB, Soeller WC, Boettner WA, Wisniecki P, Plowchalk DR, Gernhardt SS, Tracey WR, Knight DR.

Cardiovasc Drugs Ther. 2005 Oct;19(5):337-46.

PMID:
16382296
19.

Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia.

Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL, Gibbs EM, Zawalich WS, Rollema H.

Diabetes. 2005 May;54(5):1552-8.

20.

Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitors.

Ercan-Fang N, Taylor MR, Treadway JL, Levy CB, Genereux PE, Gibbs EM, Rath VL, Kwon Y, Gannon MC, Nuttall FQ.

Am J Physiol Endocrinol Metab. 2005 Sep;289(3):E366-72. Epub 2005 Mar 29.

21.

Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase.

Harwood HJ Jr, Petras SF, Hoover DJ, Mankowski DC, Soliman VF, Sugarman ED, Hulin B, Kwon Y, Gibbs EM, Mayne JT, Treadway JL.

J Lipid Res. 2005 Mar;46(3):547-63. Epub 2004 Dec 16.

22.

5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.

Wright SW, Rath VL, Genereux PE, Hageman DL, Levy CB, McClure LD, McCoid SC, McPherson RK, Schelhorn TM, Wilder DE, Zavadoski WJ, Gibbs EM, Treadway JL.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):459-65.

PMID:
15603973
23.

Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor.

Tracey WR, Treadway JL, Magee WP, Sutt JC, McPherson RK, Levy CB, Wilder DE, Yu LJ, Chen Y, Shanker RM, Mutchler AK, Smith AH, Flynn DM, Knight DR.

Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1177-84. Epub 2003 Nov 13.

24.

3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site.

Wright SW, Carlo AA, Danley DE, Hageman DL, Karam GA, Mansour MN, McClure LD, Pandit J, Schulte GK, Treadway JL, Wang IK, Bauer PH.

Bioorg Med Chem Lett. 2003 Jun 16;13(12):2055-8.

PMID:
12781194
25.

Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase.

Ekstrom JL, Pauly TA, Carty MD, Soeller WC, Culp J, Danley DE, Hoover DJ, Treadway JL, Gibbs EM, Fletterick RJ, Day YS, Myszka DG, Rath VL.

Chem Biol. 2002 Aug;9(8):915-24.

26.

Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography.

Wright SW, Carlo AA, Carty MD, Danley DE, Hageman DL, Karam GA, Levy CB, Mansour MN, Mathiowetz AM, McClure LD, Nestor NB, McPherson RK, Pandit J, Pustilnik LR, Schulte GK, Soeller WC, Treadway JL, Wang IK, Bauer PH.

J Med Chem. 2002 Aug 29;45(18):3865-77.

PMID:
12190310
27.

Integrated effects of multiple modulators on human liver glycogen phosphorylase a.

Ercan-Fang N, Gannon MC, Rath VL, Treadway JL, Taylor MR, Nuttall FQ.

Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E29-37.

28.

Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus.

Treadway JL, Mendys P, Hoover DJ.

Expert Opin Investig Drugs. 2001 Mar;10(3):439-54. Review.

PMID:
11227044
29.

Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines.

Wright SW, Hageman DL, McClure LD, Carlo AA, Treadway JL, Mathiowetz AM, Withka JM, Bauer PH.

Bioorg Med Chem Lett. 2001 Jan 8;11(1):17-21.

PMID:
11140724
30.

Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes.

Parker JC, McPherson RK, Andrews KM, Levy CB, Dubins JS, Chin JE, Perry PV, Hulin B, Perry DA, Inagaki T, Dekker KA, Tachikawa K, Sugie Y, Treadway JL.

Diabetes. 2000 Dec;49(12):2079-86.

PMID:
11118010
31.

Human liver glycogen phosphorylase inhibitors bind at a new allosteric site.

Rath VL, Ammirati M, Danley DE, Ekstrom JL, Gibbs EM, Hynes TR, Mathiowetz AM, McPherson RK, Olson TV, Treadway JL, Hoover DJ.

Chem Biol. 2000 Sep;7(9):677-82.

32.

Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase.

Parker JC, VanVolkenburg MA, Levy CB, Martin WH, Burk SH, Kwon Y, Giragossian C, Gant TG, Carpino PA, McPherson RK, Vestergaard P, Treadway JL.

Diabetes. 1998 Oct;47(10):1630-6.

PMID:
9753303
33.

Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase.

Hoover DJ, Lefkowitz-Snow S, Burgess-Henry JL, Martin WH, Armento SJ, Stock IA, McPherson RK, Genereux PE, Gibbs EM, Treadway JL.

J Med Chem. 1998 Jul 30;41(16):2934-8. No abstract available.

PMID:
9685232
34.

Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo.

Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, Treadway JL.

Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1776-81.

35.

Glucose transport-enhancing and hypoglycemic activity of 2-methyl-2-phenoxy-3-phenylpropanoic acids.

Sarges R, Hank RF, Blake JF, Bordner J, Bussolotti DL, Hargrove DM, Treadway JL, Gibbs EM.

J Med Chem. 1996 Nov 22;39(24):4783-803.

PMID:
8941393
36.

Enhanced peripheral glucose utilization in transgenic mice expressing the human GLUT4 gene.

Treadway JL, Hargrove DM, Nardone NA, McPherson RK, Russo JF, Milici AJ, Stukenbrok HA, Gibbs EM, Stevenson RW, Pessin JE.

J Biol Chem. 1994 Nov 25;269(47):29956-61.

37.

Transgenic mice expressing the human GLUT4/muscle-fat facilitative glucose transporter protein exhibit efficient glycemic control.

Liu ML, Gibbs EM, McCoid SC, Milici AJ, Stukenbrok HA, McPherson RK, Treadway JL, Pessin JE.

Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11346-50.

38.
40.

Effect of prior exercise and insulin on potential thermogenic systems in rat skeletal muscle.

Balon TW, Treadway JL, Hughes JB, Young JC, Ruderman NB.

J Appl Physiol (1985). 1992 Jun;72(6):2203-9.

PMID:
1629074
41.

Exercise in pregnancy.

Clapp JF 3rd, Rokey R, Treadway JL, Carpenter MW, Artal RM, Warrnes C.

Med Sci Sports Exerc. 1992 Jun;24(6 Suppl):S294-300. No abstract available.

PMID:
1625554
42.

The effect of prior exercise on oral glucose tolerance in late gestational women.

Young JC, Treadway JL.

Eur J Appl Physiol Occup Physiol. 1992;64(5):430-3.

PMID:
1612082
43.

Insulin/IGF-1 hybrid receptors: implications for the dominant-negative phenotype in syndromes of insulin resistance.

Frattali AL, Treadway JL, Pessin JE.

J Cell Biochem. 1992 Jan;48(1):43-50. Review.

PMID:
1316361
44.

Differential regulation of glucose transporter activity and expression in red and white skeletal muscle.

Richardson JM, Balon TW, Treadway JL, Pessin JE.

J Biol Chem. 1991 Jul 5;266(19):12690-4.

45.
46.

Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor I hybrid receptors.

Treadway JL, Morrison BD, Soos MA, Siddle K, Olefsky J, Ullrich A, McClain DA, Pessin JE.

Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):214-8.

47.

The endogenous functional turkey erythrocyte and rat liver insulin receptor is an alpha 2 beta 2 heterotetrameric complex.

Treadway JL, Morrison BD, Wemmie JA, Frias I, O'Hare T, Pilch PF, Pessin JE.

Biochem J. 1990 Oct 1;271(1):99-105.

48.

Effect of insulin on protein synthesis and degradation in skeletal muscle after exercise.

Balon TW, Zorzano A, Treadway JL, Goodman MN, Ruderman NB.

Am J Physiol. 1990 Jan;258(1 Pt 1):E92-7.

PMID:
2405703
49.

Failure of prior low-intensity exercise to potentiate the thermic effect of glucose.

Treadway JL, Young JC.

Eur J Appl Physiol Occup Physiol. 1990;60(5):377-81.

PMID:
2369909
50.

Assembly of insulin/insulin-like growth factor-1 hybrid receptors in vitro.

Treadway JL, Morrison BD, Goldfine ID, Pessin JE.

J Biol Chem. 1989 Dec 25;264(36):21450-3.

Supplemental Content

Loading ...
Support Center